Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 10;37(32):2961-2967.
doi: 10.1200/JCO.19.01595. Epub 2019 Sep 10.

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy

David J VanderWeele  1 , Emmanuel S Antonarakis  2 , Michael A Carducci  2 , Robert Dreicer  3 , Karim Fizazi  4 , Silke Gillessen  5 , Celeste S Higano  6 , Alicia K Morgans  1 , Daniel P Petrylak  7 , Christopher J Sweeney  8 , Maha Hussain  1
Affiliations

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy

David J VanderWeele et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

David J. VanderWeele

Travel, Accommodations, Expenses: Genzyme

Emmanuel S. Antonarakis

Honoraria: Sanofi, Dendreon, Medivation, Janssen Pharmaceuticals, ESSA, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology

Consulting or Advisory Role: Sanofi, Dendreon, Medivation, Janssen Pharmaceuticals, ESSA, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology

Research Funding: Janssen Pharmaceuticals (Inst), Johnson & Johnson (Inst), Sanofi, (Inst), Dendreon (Inst), Aragon Pharmaceuticals (Inst), Exelixis (Inst), Millennium Pharmaceuticals (Inst), Genentech (Inst), Novartis (Inst), Astellas Pharma (Inst), Tokai Pharmaceuticals (Inst), Merck (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), Constellation Pharmaceuticals (Inst)

Patents, Royalties, Other Intellectual Property: Co-inventor of a biomarker technology that has been licensed to QIAGEN

Travel, Accommodations, Expenses: Sanofi, Dendreon, Medivation

Michael A. Carducci

Consulting or Advisory Role: Astellas Pharma, AbbVie, Roche, Genentech, Pfizer, Foundation Medicine

Research Funding: Bristol-Myers Squibb (Inst), Pfizer (Inst), AstraZeneca (Inst), Gilead Sciences (Inst), EMD Serono (Inst), eFFECTOR Therapeutics (Inst)

Robert Dreicer

Consulting or Advisory Role: Astellas Pharma, AstraZeneca, Genentech, Roche, EMD Serono, Incyte, Pfizer, Eisai, Janssen Pharmaceuticals, Modra Pharmaceuticals

Research Funding: Genentech (Inst), Seattle Genetics (Inst), BioClin Therapeutics (Inst), Janssen Pharmaceuticals (Inst), Merck (Inst)

Karim Fizazi

Honoraria: Janssen Pharmaceuticals, Sanofi, Astellas Pharma

Consulting or Advisory Role: Janssen Pharmaceuticals, Bayer AG, Astellas Pharma, Sanofi, Orion Pharma, Curevac, AstraZeneca, ESSA, Roche, Genentech, Amgen

Travel, Accommodations, Expenses: Amgen, Janssen Pharmaceuticals

Silke Gillessen

Honoraria: Janssen Pharmaceuticals

Consulting or Advisory Role: Astellas Pharma (Inst), Curevac (Inst), Novartis (Inst), Active Biotech (Inst), Bristol-Myers Squibb (Inst), Ferring Pharmaceuticals (Inst), MaxiVax, Advanced Accelerator Applications, Roche, Janssen Pharmaceuticals (Inst), Innocrin Pharma (Inst), Sanofi, Bayer AG, Orion Pharma, Clovis Oncology (Inst), Menarini Silicon Biosystems (Inst)

Patents, Royalties, Other Intellectual Property: Method for biomarker (WO 3752009138392 A1)

Other Relationship: Nektar, ProteoMediX

Celeste S. Higano

Employment: CTI (I)

Leadership: CTI (I)

Stock and Other Ownership Interests: CTI (I)

Consulting or Advisory Role: Bayer AG, Ferring Pharmaceuticals, Astellas Pharma, Clovis Oncology, Blue Earth Diagnostics, Myriad Genetics, Tolmar, Janssen Pharmaceuticals, Hinova Pharmaceuticals, Pfizer, AstraZeneca

Research Funding: Aragon Pharmaceuticals (Inst), AstraZeneca (Inst), Dendreon (Inst), Medivation (Inst), Emergent BioSolutions (Inst), Bayer AG (Inst), Pfizer (Inst), Roche (Inst), Astellas Pharma (Inst)

Travel, Accommodations, Expenses: Bayer AG, Astellas Pharma, Clovis Oncology, Blue Earth Diagnostics, Ferring Pharmaceuticals, Menarini, Myriad Genetics, Pfizer, Hinova Pharmaceuticals

Alicia K. Morgans

Honoraria: Genentech, Janssen Pharmaceuticals, Sanofi, AstraZeneca, Astellas Pharma, Astellas Colombia, Bayer AG

Consulting or Advisory Role: Genentech, AstraZeneca, Sanofi, Bayer AG, Astellas Pharma, Janssen Pharmaceuticals

Research Funding: Bayer AG, Seattle Genetics, Astellas Pharma, Genentech, AstraZeneca

Travel, Accommodations, Expenses: Sanofi

Daniel P. Petrylak

Stock and Other Ownership Interests: Bellicum Pharmaceuticals, TYME

Consulting or Advisory Role: Bayer AG, Exelixis, Pfizer, Roche, Astellas Pharma, AstraZeneca, Eli Lilly, Ada Cap, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Incyte, Janssen Pharmaceuticals, Pharmacyclics, Seattle Genetics, Urogen Pharma

Research Funding: Progenics (Inst), Sanofi (Inst), Endocyte (Inst), Genentech (Inst), Merck (Inst), Astellas Pharma (Inst), Medivation (Inst), Novartis (Inst), AstraZeneca (Inst), Bayer AG (Inst), Eli Lilly (Inst), Innocrin Pharma (Inst), MedImmune (Inst), Pfizer (Inst), Roche (Inst), Seattle Genetics (Inst), Clovis Oncology (Inst), Ada Cap (Inst), Bristol-Myers Squibb (Inst)

Expert Testimony: Celgene, Sanofi

Christopher J. Sweeney

Stock and Other Ownership Interests: Leuchemix

Consulting or Advisory Role: Sanofi, Janssen Pharmaceuticals, Astellas Pharma, Bayer AG, Genentech, Roche, AstraZeneca, Pfizer, Amgen, Celgene, Eli Lilly

Research Funding: Janssen Pharmaceuticals (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer AG (Inst), Sotio (Inst), Dendreon (Inst)

Patents, Royalties, Other Intellectual Property: Leuchemix, parthenolide, dimethylaminoparthenolide; Exelixis, abiraterone plus cabozantinib combination

Maha Hussain

Honoraria: Onclive, Sanofi, Genzyme, Physicians’ Education Resource, Projects in Knowledge, PER, Genentech, Astellas

Consulting or Advisory Role: Pfizer, AstraZeneca, Bayer

Research Funding: Genentech (Inst), Pfizer (Inst), The Prostate Cancer Clinical Trials Consortium (Inst), AstraZeneca (Inst), Bayer (Inst)

Patents, Royalties, Other Intellectual Property: Title: Systems and Methods for Tissue Imaging, 3676. Our file: serial number UM-14437/US-1/PRO 60/923,385, UM-14437/US-2/ORD 12/101,753, US 8,185,186 (US patent number). Systems and methods for tissue imaging (issued patent) EP 08745653.9 (EP application number). Systems and methods for tissue imaging (pending) CA 2683805 (Canadian application number). Systems and methods for tissue imaging (pending) US 13/362,500 (US application number). Systems and methods for tissue imaging (continuation application of US 8,185,186). Title: Method of Treating Cancer. Docket number: serial number 224990/10-016P2/311733 61/481/671. Application filed on May 2, 2011. Title: Dual Inhibition of MET and VEGF for the Treatment of Castration Resistant Prostate Cancer and Osteoblastic Bone Metastases. Applicant/proprietor Exelixis. Application number/patent number 11764665.4-1464. Application number/patent number 11764656.2-1464. Application filed on September 26, 2011

Travel, Accommodations, Expenses: Sanofi, Astellas, Bayer

No other potential conflicts of interest were reported.

References

    1. Kantoff PW, Higano CS, Shore ND, et al. : Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422, 2010 - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147–1154, 2010 - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005, 2011 - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, et al. : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197, 2012 - PubMed
    1. Parker C, Nilsson S, Heinrich D, et al. : Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223, 2013 - PubMed